Bioelectronic cell-based device provides a strategy for the treatment of the experimental model of multiple sclerosis

• DOI: 10.1016/j.jconrel.2022.11.008
• Publication Date: 2022-11-16T23:14:25Z
• Authors: Emilie Audouard; Fanny Michel; Vanessa Pierroz; Taeuk Kim; Lisa Rousselot; Béatrix Gillet-Le...; Gaëlle Dufayet-Ch...; Peter Buchmann; Michael Florea; Alexander Khel; Kamilya Altynbekova; Claudia Delgaldo; Encarna Escudero; Alejandra Ben Ais...; Nathalie Cartier; Francoise Piguet; Marc Folcher
• Keywords: 0301 basic medicine; 0303 health sciences; Multiple Sclerosis; Encephalomyelitis, Autoimmune, Experimental; Cell-based device; Optogenetic; Bioelectronic; Drug delivery; Multiple sclerosis; Interferon; Gene Expression; Interferon-beta; Bioelectronic; Cell-based device; Article; 3. Good health; Mice, Inbred C57BL; Multiple sclerosis; Mice; Disease Models, Animal; 03 medical and health sciences; Drug delivery; Animals; Humans; Interferon; Optogenetic

Wireless powered optogenetic cell-based implant provides a strategy to deliver subcutaneously therapeutic proteins. Immortalize Human Mesenchymal Stem Cells (hMSC-TERT) expressing the bacteriophytochrome diguanylate cyclase (DGCL) were validated for controlled interferon-β delivery (Optoferon cells) in bioelectronic implant. Optoferon cells transcriptomic profiling was used elaborate an in-silico model of recombinant production. optoelectronic device integration developed using additive manufacturing and injection molding. Implant interface established integrate industrial flexible compact low-resistance screen-printed Near Field Communication (NFC) coil antenna. Optogenetic biocompatibility, performances evaluated Experimental Autoimmune Encephalomyelitis (EAE) mouse multiple sclerosis.